SOW
KPTI icon

State of Wyoming’s Karyopharm Therapeutics KPTI Stock Holding History

State of Wyoming’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,512
Closed -$71.7K – 1806
2024
Q2 		$71.7K Buy
5,512
+2,358
+75% +$39K 0.01% 1219
2024
Q1 		$71.4K Buy
3,154
+1,259
+66% +$22.1K 0.01% 1180
2023
Q4 		$24.6K Sell
1,895
-821
-30% -$11.1K ﹤0.01% 1532
2023
Q3 		$54.6K Buy
+2,716
New +$61K 0.01% 1223
2023
Q1 		– Sell
-1,139
Closed -$58.1K – 1694
2022
Q4 		$58.1K Buy
1,139
+745
+189% +$51.6K 0.02% 1016
2022
Q3 		$32K Sell
394
-313
-44% -$23.4K 0.02% 1167
2022
Q2 		$48K Sell
707
-301
-30% -$27.6K 0.03% 965
2022
Q1 		$111K Buy
1,008
+46
+5% +$5.73K 0.06% 518
2021
Q4 		$93K Buy
962
+62
+7% +$6.18K 0.04% 690
2021
Q3 		$79K Sell
900
-60
-6% -$6.23K 0.05% 559
2021
Q2 		$149K Buy
+960
New +$139K 0.09% 283

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State of Wyoming's KPTI Position: Q3 2024 in Review

State of Wyoming sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 5,512 shares — an estimated $71.7K sold.

State of Wyoming first reported a position in KPTI in Q2 2021 and held it in 11 quarters. The position peaked at $149K in Q2 2021. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • State of Wyoming reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • State of Wyoming sold 5,512 Karyopharm Therapeutics shares in Q3 2024, an estimated $71.7K.
  • State of Wyoming first reported a position in Karyopharm Therapeutics in Q2 2021 and held it in 11 quarters.
  • State of Wyoming's Karyopharm Therapeutics position peaked at $149K in Q2 2021.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on State of Wyoming's 13F filing for Q3 2024, filed 14 Nov 2024.